Crohn's Disease Clinical Trial
Official title:
A Four Part, Phase 1, First Time in Human, Single Centre Study in Healthy Male Subjects, Patient Volunteers With Crohn's Disease and in Healthy Patient Volunteers With a Terminal Ileostomy
A multi-part study to investigate the safety, tolerability and local and systemic pharmacokinetics of V565
Status | Completed |
Enrollment | 47 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Parts 1 and 2 1. Adult male subjects aged 18 to 45 years inclusive. 2. Body mass index (BMI) between 18.0 and 32.0 kg/m2 inclusive. 3. Body weight between 50.0 and 100.0 kg inclusive. 4. Subjects who are healthy as determined by pre study medical history, physical examination and 12-lead ECG, and clinical laboratory tests - Part 3 1. Adult male or female subjects aged 18 to 65 years. 2. Ileostomy for a minimum of 18 months for a non malignant disease indication. 3. A BMI between 18.0 and 32.0 kg/m2 inclusive. 4. Body weight between 50.0 and 100.0 kg inclusive. 5. Subjects who are healthy as determined by pre study medical history, physical examination and 12-lead ECG, and clinical laboratory tests - Part 4 1. Adult male or female subjects aged 18 to 65 years. 2. A confirmed diagnosis of Crohn's disease for a minimum of 6 months. 3. A BMI between 15.0 and 32.0 kg/m2 inclusive. 4. Subjects who have no other significant co-morbidity (other than those associated with Crohn's disease). 5. Subjects whose medical history, physical examination, clinical laboratory test results and 12-lead ECG have no clinically relevant abnormalities (other than those associated with Crohn's disease). Exclusion Criteria: - Parts 1 and 2 1. A clinically significant abnormal medical history or clinically significant abnormal physical examination, including history of febrile illness within 1 week prior to the first dose. 2. A history of severe allergies, non-allergic drug reactions, or multiple drug allergies. 3. A known hypersensitivity to TNF inhibitors or any of the inactive ingredients of the study treatment. 4. A history of significant gastrointestinal (GI) disease, including GI motility disorders, GI malignancy or of polyposis coli. 5. Previous surgery to the GI tract with the exception of appendectomy. 6. A history of malignancy. 7. Any other condition which in the investigator's opinion will interfere with the trial or interpretation of the results. - Part 3 1. A history of Crohn's disease. 2. A clinically significant abnormal medical history (other than the condition leading to ileostomy) or clinically significant abnormal physical examination, including history of febrile illness within 1 week prior to the first dose. 3. A history of severe allergies, non-allergic drug reactions, or multiple drug allergies. 4. A known hypersensitivity or contraindication to TNF inhibitors or any of the inactive ingredients of the study treatment. 5. A known history of heart disease. 6. Any clinical evidence of active inflammatory bowel disease. 7. Any other condition which in the investigator's opinion will interfere with the trial or interpretation of the results. - Part 4 1. Subjects with severe Crohn's disease such as: those requiring surgery; those with a current abscess; those with a non inflammatory stricture; those with a history of obstruction. 2. Having ever received anti-TNF-a therapy or other biologics. 3. Required an increase in dose of either steroids or immunosuppressant therapy within the past 6 weeks. |
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)
Country | Name | City | State |
---|---|---|---|
United Kingdom | Quintiles Drug Research Unit at Guy's Hospital, Quintiles Ltd | London |
Lead Sponsor | Collaborator |
---|---|
VHsquared Ltd. |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety & tolerability: treatment-emergent AEs including clinically significant changes in physical examinations, safety lab tests, ECGs or vital signs | Up to 14 days | Yes | |
Primary | Measurement of the concentrations of V565 in ileal fluid following a single dose | 24 hours | No | |
Secondary | Evaluation of pharmacokinetic parameter of V565: Cmax | 72 hours | No | |
Secondary | Evaluation of pharmacokinetic parameter of V565: AUC | 72 hours | No | |
Secondary | Evaluation of pharmacokinetic parameter of V565: tmax | 72 hours | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03815851 -
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
|
N/A | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Completed |
NCT02883452 -
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT04777656 -
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
|
Phase 3 | |
Terminated |
NCT03017014 -
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
|
||
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Recruiting |
NCT06053424 -
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
|
Phase 1 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Terminated |
NCT02882841 -
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
|
N/A | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
Terminated |
NCT02417974 -
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
|
Phase 2 | |
Completed |
NCT02542917 -
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
|
||
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
Completed |
NCT02193048 -
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
|
||
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Recruiting |
NCT02395354 -
Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease
|
N/A | |
Completed |
NCT01958827 -
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
|
Phase 3 | |
Completed |
NCT01951326 -
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
|
Phase 3 |